Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 08, 2023 9:30am

157 Views

Post# 35723315

RE:RE:RE:RE:ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023

Big catalysts are on our doorstep. People seemed more upbeat last year when we were just purely speculating about PFE and the 90 day exclusivity. This year we await certain news on PanCan, partners and the FDA. The SP still reeks and it's tough that the Ubers, Tams and Armedescapes of the world have thus far called things better than the cheerleaders, but a win is coming....Good luck all!!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing